A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer.
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Mar 2014 According to ClinicalTrials.gov record, the trial phase changed from I/II to I.
- 12 Mar 2014 According to ClinicalTrials.gov record, the trial phase changed from I/II to I.
- 12 Mar 2014 New source identified and integrated (ClinicalTrials.gov; NCT02087839).